Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analyst sentiment is bullish: Fourteen analysts give Dianthus Therapeutics a consensus “Moderate Buy” rating, with 12 buy ratings, one strong buy, and one sell. The average 12-month price target is $124.27.
• Shares are near a 52-week high: DNTH opened at $115.54, up 0.6%, with a market capitalization of approximately $6.32 billion. The stock has risen substantially from its 52-week low of $20.69.
• The company remains unprofitable and insiders have been selling: Dianthus reported a quarterly loss of $0.90 per share, worse than the expected $0.85 loss, despite revenue exceeding estimates. Insiders sold approximately $29.3 million worth of shares over the past 90 days.

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fourteen research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, twelve have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $124.2727.

DNTH has been the subject of several research analyst reports. Wall Street Zen upgraded shares of Dianthus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Guggenheim reiterated a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Truist Financial boosted their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, Wolfe Research reissued an "outperform" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th.

Dianthus Therapeutics Trading Up 0.6%

Shares of NASDAQ:DNTH opened at $115.54 on Wednesday. The company has a market capitalization of $6.32 billion, a PE ratio of -27.84 and a beta of 1.22. Dianthus Therapeutics has a twelve month low of $20.69 and a twelve month high of $116.89. The firm has a 50 day simple moving average of $98.77 and a 200-day simple moving average of $83.98.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. As a group, equities research analysts predict that Dianthus Therapeutics will post -3.83 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Anne Mcgeorge sold 7,750 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the sale, the director directly owned 1,250 shares of the company's stock, valued at approximately $136,262.50. This represents a 86.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the sale, the executive vice president directly owned 31,249 shares of the company's stock, valued at $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 284,306 shares of company stock valued at $29,289,369 in the last 90 days. Company insiders own 3.02% of the company's stock.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently bought and sold shares of DNTH. ABS Investment Management LLC purchased a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $194,960,000. PNC Financial Services Group Inc. boosted its stake in shares of Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company's stock worth $3,135,000 after buying an additional 139 shares during the period. First Horizon Corp purchased a new position in shares of Dianthus Therapeutics during the first quarter worth about $32,000. Virtus Investment Advisers LLC grew its holdings in shares of Dianthus Therapeutics by 7.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company's stock worth $260,000 after buying an additional 416 shares during the last quarter. Finally, EFG International AG acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at about $49,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source